Nitroglycerine SR DC Granules are pharmaceutical-grade granulated materials designed for sustained-release formulation development and direct-compression applications. The SR DC format combines two important formulation concepts: sustained-release performance and direct-compression processing. The finished granule system must therefore be designed and controlled to provide appropriate physical properties for processing together with a validated release profile.
Nitroglycerine, also known as glyceryl trinitrate, has the molecular formula C3H5N3O9, molecular weight 227.09 g/mol and CAS Number 55-63-0. Pharmaceutical formulations containing nitroglycerine require careful control of composition, content uniformity, stability and release characteristics. USP information for diluted nitroglycerine identifies C3H5N3O9 and CAS 55-63-0 and describes diluted material as nitroglycerine combined with suitable inert excipients for controlled pharmaceutical handling. The exact finished-product specification for Nitroglycerine SR DC Granules should be based on the approved product specification and validated analytical procedures.
Nitroglycerine SR DC Granules are engineered granules intended for sustained-release and direct-compression formulation applications. In this format, the granulated material is designed to provide controlled physical characteristics for blending and compression while the sustained-release behavior is achieved through the complete formulation or release-control system.
The term DC refers to Direct Compression, meaning the material is developed for incorporation into a formulation that can be compressed after appropriate blending without requiring a conventional granulation step immediately before tablet compression.
The term SR refers to Sustained Release. Sustained-release behavior is not an inherent property of nitroglycerine itself; it depends on the formulation architecture, matrix or coating system, excipient selection and validated release characteristics.
Nitroglycerine has the molecular formula C3H5N3O9 and molecular weight 227.09 g/mol. Its CAS Number is 55-63-0.
Because nitroglycerine is a potent active ingredient used at relatively low quantities in pharmaceutical formulations, content uniformity and accurate analytical control are important formulation considerations. The active component must be distributed consistently throughout the granulated material and the final dosage form.
USP information for diluted nitroglycerine describes a pharmaceutical mixture containing nitroglycerine with suitable inert excipients and specifies a labeled-content range for that particular diluted material. This specification should not be transferred directly to a finished Nitroglycerine SR DC Granules product unless the finished product has been validated against the same specification and analytical basis.
Sustained-release formulations are designed to modify the rate at which an active component becomes available from the dosage form. For Nitroglycerine SR DC Granules, release control may be achieved through an appropriate matrix, polymeric barrier, coating system or other validated formulation mechanism.
Published research has examined the use of acrylic polymers and ethylcellulose to reduce the release rate of nitroglycerine from granulated systems. The extent of release modification depends on the type and amount of release-controlling material and the overall formulation design.
Therefore, a commercial Nitroglycerine SR DC Granules specification should define its release characteristics using product-specific validated dissolution or release testing rather than relying on a generic sustained-release claim.
Direct compression requires suitable flow and compaction characteristics. Granules used for direct compression should provide controlled particle-size distribution, appropriate bulk density, consistent flow and suitable compression behavior.
Important physical characteristics can include:
These characteristics should be controlled according to the approved product specification and actual manufacturing data.
Particle-size distribution can influence flow, packing, blend uniformity and compression behavior. Consistent granule size can support more predictable material movement and reduce variability during blending and die filling.
Nitroglycerine SR DC Granules may therefore be evaluated for particle-size distribution and relevant granule fractions. D10, D50 and D90 can be used as development and quality-control parameters when they are part of the approved specification.
The appropriate particle-size range is product-specific and should not be represented by a generic numerical value without validated product data.
Flowability is an important consideration for direct-compression formulations. Controlled flow characteristics can support consistent transfer, blending and die filling.
Potential evaluation parameters include:
The actual acceptance criteria should be established according to the finished-product specification and validated test methods.
For sustained-release direct-compression systems, both flow characteristics and release performance must be considered because changes in particle size, density or formulation composition can affect processing and final dosage-form behavior.
Compressibility and compactability are important for direct-compression materials. Compressibility describes the reduction in volume of a particulate system under applied pressure, while compactability describes the ability of the material to form a mechanically suitable compact.
Nitroglycerine SR DC Granules should be evaluated as part of the complete formulation because tablet strength, porosity, disintegration behavior and release characteristics can be influenced by compression conditions.
Published research on sustained-release direct-compression systems demonstrates that raw-material flowability, compression conditions and tablet properties can influence reproducible dissolution behavior. Consequently, compression development should be linked with release testing rather than evaluated only from tablet hardness.
Content uniformity is a critical quality consideration for formulations containing a potent active component at relatively low concentration.
The granule system should be developed to provide appropriate distribution of the active component. Relevant development assessments can include:
Finished-product acceptance criteria should be established using validated analytical methods and the approved specification.
The principal functional characteristic of Nitroglycerine SR DC Granules is controlled release. The release profile depends on the complete formulation system rather than on the active component alone.
Release control can be influenced by:
A specific release duration such as 8, 12 or 24 hours should not be claimed unless supported by validated product-specific dissolution data.
Dissolution testing is particularly important for sustained-release products. The release profile should be established using an appropriate validated analytical method and dissolution procedure.
Potential development assessments include:
The actual dissolution limits and time points should be taken from the approved finished-product specification.
Quality control of Nitroglycerine SR DC Granules should include chemical, physical and performance-related attributes.
Depending on the approved specification, relevant quality attributes may include:
Not every test applies universally. The final testing panel should correspond to the actual formulation, manufacturing process and approved product specification.
Development of Nitroglycerine SR DC Granules requires evaluation of both processing and release performance.
Formulation development may examine the relationship between granule properties and final dosage-form performance. Particle size can influence flow and packing, while the release-control system can determine the rate of active-component release.
The formulation may also require assessment of compatibility between nitroglycerine and the selected excipient system. Stability, content uniformity and release-profile consistency should be evaluated during development.
Nitroglycerine SR DC Granules may be considered for formulation-development applications involving:
The final dosage form and intended application should be determined according to the approved formulation and applicable pharmaceutical requirements.
Nitroglycerine-containing materials require specialized pharmaceutical quality systems and appropriate controls because the active component has significant safety and handling considerations.
For a commercial granule product, quality should be supported through controlled raw materials, validated analytical methods, appropriate process controls, environmental controls and documented batch-release procedures.
The product specification should clearly distinguish between raw-material requirements and finished Nitroglycerine SR DC Granules requirements. API specifications should not automatically be presented as finished-granule specifications.
Stability is an important consideration for Nitroglycerine-containing formulations. The finished product should be evaluated under appropriate stability conditions using validated analytical methods.
Relevant stability attributes may include:
Specific storage conditions and shelf-life claims should only be published when supported by the actual product stability program and approved product documentation.
A comprehensive quality-control approach can combine chemical testing, physical characterization and release testing.
Chemical testing can confirm identity, assay and relevant impurities. Physical characterization can assess particle size, density, flow and moisture. Performance testing can evaluate sustained-release behavior and batch-to-batch consistency.
The exact acceptance limits should be based on the approved product specification. Generic numerical values should not be substituted for validated product-specific criteria.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white granules |